Why human lifespan is rapidly increasing: solving "longevity riddle"


































Unexpected increase in longevity 
 
Death from aging is technically death from age-related 
diseases, which are manifestations of advanced aging 
[1]. But, historically, most people died young and, of 
course, not from age-related diseases but, rather, from 
starvation and epidemics (cholera, smallpox, 
tuberculosis and many currently rare infections) as well 
as from physical violence. Just three centuries ago, life 
expectancy was less than 16 years and 75% of people 
born in London in 1662 died before they reached the 
age of 26 (Graunt’s life table). The progress of 
civilization eliminated many causes of death that killed 
young people in the past. This dramatically increased 
the average lifespan. In addition, modern medicine 
extended lifespan of old people by treating age-related 
diseases. But maximal lifespan seemed to be not 
affected. It was assumed that human life span is close to 
its upper limits. However, surprising demographists and 




































tinues to increase at an astonishing pace  [2, 3]. In the 
countries with the highest life expectancies, the long 
term increase in life expectancy proceeds at a pace of 
2.5 years per 10 years, or six hours per day [4]. A 
century ago, the chance to become centenarian (a person 
older than 100 years) was a hundred times lower. 
Furthermore, as calculated, most babies born since 2000 
in countries with long life expectancies will celebrate 
their 100th birthdays [5]. Most astonishingly, people are 
reaching very old age in better health. But then they 
deteriorate fast, seemingly indicating that the rate of 
aging was not changed but just aging was postponed 
[3]. “Taken together, these findings are so perplexing 
that they can be dubbed the ‘longevity riddle’: why do 
the evolutionary forces that shaped human aging 
provide a license to alter the level of health but not the 
rate of debilitation?” [3]. So why can aging be delayed 
but not slowed? Or can aging be slowed? In order to 
solve the longevity riddle, we should turn gerontology 
on its head. It has been always assumed that aging is 





















at  the  expense  of  accelerated  aging.  In  other  words,  robustness  and  fast  aging  may  be  associated  and  slow‐aging
individuals died prematurely in the past. Therefore, until recently, mostly fast‐aging individuals managed to survive into
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driven by damage, but, in contrast, leads to damage 
(organ damage) [6-8]. And aging is driven in part by 
mTOR (mammalian target of rapamycin). 
 
TOR-driven quasi-programmed aging and age-
related diseases 
 
The mTOR intracellular signaling pathway is activated 
by numerous signals including glucose, amino acids, fat 
acids and other nutrients, insulin and some other 
hormones, growth factors and cytokines [9-11]. In 
response, it increases cellular functions and cellular 
mass growth [12]. When the cell cycle is blocked, 
mTOR drives cellular senescence [13]. Cellular aging 
can be defined as over-activation of signaling pathways 
(such as mTOR) with secondary signal resistance [14]. 
In turn this slowly leads to diseases of aging 
(hypertension, atherosclerosis, macular degeneration, 
insulin resistance, obesity, neurodegeneration, cancer, 
osteoporosis, organ hypertrophy). For example, TOR-
dependent activation of osteoclasts causes bone 
resorption (osteoporosis) [15]. But these aging 
processes are relatively silent (subclinical, no obvious 
deterioration) until aging culminates in “catastrophes” – 
organ damage. For example, osteoporosis can lead to 
broken hip and atherosclerosis can lead to infarction. 
Then deterioration can be quick, leading to death in a 
mater of hours or years or decades, depending on the 




When diseases become clinical then deterioration may be 
fast. For example, high blood pressure, thrombosis and 
atherosclerosis can culminate in stroke. This will initiate 
a chain of deteriorations (immobility – pneumonia, etc.) 
that are TOR-independent.  The duration of this morbid 
(deterioration) phase is almost solely determined by the 
level of medical care. Furthermore, age-related blindness 
and Alzheimer’s disease are rarely lethal anymore. 
Medicine may dramatically prolong the morbidity phase, 
delaying death. Thus, the speed of deterioration is almost 
independent from the aging process and cannot serve as a 
marker of aging or the rate of aging. The rate of aging is 
actually determined by the age of the onset of age-related 
diseases. Slowing down the aging process (by calorie 
restriction, rapamycin or genetic manipulation) delays 
diseases.  
 
 “Thought experiment”: how would rapamycin 
affect longevity in 1667 versus 1967 
 
Rapamycin is an anti-aging drug, which is currently 
used to prevent donor organ rejections [16].  Rapamycin 
delays cancer in animals and humans (see for review 
[17]). It also delays other age-related diseases in animal 
models of accelerated diseases. For example, rapamycin 
and its analogs delay atherosclerosis [18-23]. mTOR is 
involved in age-related diseases exactly because it is 
involved in aging. In fact, rapamycin prolongs life span 
in mice and flies [24-27]. It is expected that, in adult 
humans, rapamycin (at correct doses and schedules) will 
prolong healthy and maximal lifespan [16]. But 
consider rapamycin administered for life, starting from 
childhood. Then its effect on longevity will depend on 





Scenario 1.  Assume that in 1667, 3 out of 4 newborns 
were randomly prescribed rapamycin for life. 
Rapamycin would slow down developmental growth (a 
disadvantage for survival, especially for orphans). 
Malnutrition and stresses would be less tolerated, 
because the nutrient sensing pathway is deactivated by 
rapamycin. Reduced muscle mass and fat stores would 
increase chances of death from violence and famine. In 
infants with natural immunotolerance, rapamycin would 
further decrease immunity against infections, which 
were numerous, incurable and non-preventable in 17
th 
century. So, if 3 out of 4 people must die before the age 
of 26 (1667 in London), they would be those who were 
treated with rapamycin. The control group would 
survive and develop diseases of aging at normal (early) 
age.  
 
Scenario 2. In 20
th century London, sanitation, 
vaccination and other measures have greatly reduced 
epidemics. The discovery of antibiotics has further 
prevented death from infections. Famine and violent 
death are not common either. Those who were treated 
with rapamycin for life will survive into adulthood and 
then will age slowly.  In the rapamycin-treated group, 
diseases will be delayed. Furthermore, even its ability to 
cause immunologic tolerance (‘rejuvenate’ immunity) 
will be beneficial in the elderly by decreasing hyper-
immunity and autoimmunity. (Note: rapamycin 
improves immunity in old animals [28]).  So, now, the 
rapamycin treated group becomes centenarians in good 
heath. But because deterioration is mTOR-independent, 
this group will deteriorate at the same rate (but later in 
life) as the control group, assuming that the medical 
treatment is equal in both groups (in reality, younger 
patients are treated more intensively.) 
 
The revealed-slow-aging hypothesis 
 
Thus, while slow aging was a disadvantage in 1667, it 
became an advantage in 1967. In the past, mostly fast-
aging individuals could survive into chronologically old 
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survive into chronologically old age (Figure 2B). 
Therefore, demographists observe an increasing number 
of individuals who are healthy at advanced 
chronological ages with delayed onset of diseases, who 
then deteriorate at the same rate as younger patients 


























Importantly, current increase in healthy lifespan 
(increased longevity with late onset of age-related 
diseases) is not caused by natural selection. It happens 
in the same generation. Slow aging was not selected but 
was simply revealed (Figure 2 B). Until recently, most 
slow-aging individuals died prematurely. They (we) did 
not necessarily die young but nevertheless died not from 
aging.  For example, at the same chronological age 
when fast-aging individuals died from heart attack, 
healthy slow-aging individuals died from malnutrition 
and infections, for instance. Elimination of premature 
death greatly enriched chronologically old population 
with slow-aging (biologically young) individuals 
(Figure 2).  
 
To be possibly correct, the hypothesis requires a high 
proportion of slow-aging individuals at birth (Figure 2).  
Otherwise, there would be too few slow-aging 
individuals to make a difference later (Figure 2 A vs B).  
Why was not slow aging selected out? Slow aging must 
be beneficial for women, by increasing their 
reproductive period. In fact, female’s fertility is 
decreasing early in life (starting from late twenties, long 
before menopause). This reproductive aging is one of 
the earliest manifestations of aging in females. So slow 
aging benefits females. Also, as I will discuss 
elsewhere, women do not need to be as robust as men, 
so can afford to age slower (see forthcoming article   
“Why men age faster but reproduce longer: mTOR 
perspective”). In turn, males inherit genes for longevity 
too, explaining a high proportion of slow-aging 
individuals at birth.  
 
The revealed-slow-aging hypothesis predicts that 
certain very harsh conditions may result in a decrease in 
healthy lifespan decades later. For example, perhaps it 
is robust (and therefore fast-aging later) young men who 
predominantly survived wars, camps and orphanages. 
(If so, the death of weak slow-aging young men during 
1940
th-1950
th might explain a drop in healthy lifespan 
of Russian men 50 years later.) Also, the hypothesis 
explains data on early-age mortality and subsequent 
mortality in the same cohorts. Thus Finch and 
Crimmins showed that increasing longevity and 
declining mortality in the elderly occurred among the 
same birth cohorts that experienced a reduction in 
mortality at younger ages [29, 30]. The revealed-slow-
aging hypothesis suggests that high levels of infection 
early in life eliminate young individuals with a ‘weak’ 
mTOR (slow-aging individuals, who otherwise would 






























Figure  2.  Preferential  survival  fast‐  versus  slow‐aging 
individuals. (A) In the past, slow‐aging individuals (open circles) 
died  prematurely  and  fast‐aging  individuals  (closed  circles)





























The prospect of longevity 
 
Today, most slow-aging individuals, with less active 
mTOR, do not die early in life from malnutrition and 
infections and can reach chronologically old age. 
Exactly because they are slow-aging (young 
biologically), they are able to reach old age in good 
health. This may explain the current increase in 
longevity. But this trend is probably close to saturation 
and will be saturated by 2050 (a century after invention 
of antibiotics) in the countries with the highest 
longevity. The reason is that the rate of aging was not 
affected by elimination of death from famine and 
infections.  
 
Yet, aging could be slowed by rapamycin, a drug 
currently approved to prevent organ rejection. (Note: 
rapamycin, as an anti-aging drug, perhaps should not be 
administrated until after growth is completed). Based on 
data with calorie restriction and rapamycin in mice, 
lifespan might be increased on 30 percent. Then we will 
observe 140-150 years old individuals and average 
lifespan will exceed 100.  
 
Solution of heath care crisis and further prospect on 
longevity 
 
Currently, by treating each disease individually and 
focusing on advanced diseases, traditional medical 

























Figure  3.  Traditional  medicine  increases  survival  (extends
deterioration phase) without affecting the onset of deterioration. 
 
So, traditional medicine increases number of old people 
in bad health. However, extension of lifespan by 
lengthening only the morbidity phase will make the cost 
of medical care unsustainable for society. Anti-aging 
medicine can solve this crisis by delaying the morbidity 
(deterioration) phase (Figure 4). 
 
There is incorrect perception that anti-aging drugs 
would increase a number of people suffering with age-
related diseases. In contrast, such old people will be 
healthy because they will be only chronologically old 
but biologically young. They will be healthier for longer 
(until they reach biological age of deterioration). 
Biological age is by itself determined by the sum of all 
diseases of aging [1]. In other words, diseases of aging 
are manifestations of biological aging. It is impossible 
to dissociate biological aging and diseases of aging. 
Healthy aging is healthy non-aging (or slow aging).  
 
Deceleration of aging, manifested as “healthy aging”, 
increases the ratio of healthy to unhealthy people 
(Figure 4). Furthermore, the ability to work is 
determined by biological age. Slow aging may delay 
retirement until later in life (as also suggested by 
Vaupel [3]) and in turn may provide the means for 
society to support further development of increasingly 
powerful (and expensive) conventional medicine. Then 
lifespan can be extended by both anti-aging medical 
intervention (to delay morbidity) and specialized 
medical intervention (to prolong morbidity stage). 
   

























In conclusion, the progress of medicine 60-100 years 
ago (in prevention and treatment of non-age-related 
diseases) allowed slow-aging individuals to survive 
long enough to die from late onset age-related diseases 
(in other words to die from postponed aging). 
Civilization increased a proportion of slow-aging 
persons among the elderly, without actually slowing the 
aging process. Rapamycin will be used to slow down 
aging itself, further extending healthy lifespan. The 
extent of lifespan extension will depend on the future 
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